Special Issue

The Role of Alternative Splicing in Cancer

Message from the Guest Editor

Since the original discovery in 1994 that the canonical isoform of the *FAS* gene bound to the mitochondrial membrane is pro-apoptotic, while a soluble isoform is anti-apoptotic, many examples of alternative splicing have been found in which both oncogenic and suppressor isoforms may be produced from the same gene. Aberrant splicing may, therefore, result in oncogenicity in otherwise normal tissue. Due to these circumstances, a great interest in the relationships between alternative splicing and cancer has arisen in the last few years. I am pleased to invite you to contribute to this Special Issue of *Cancers*, which tries to gather relevant papers supporting the increasing importance of those relationships. Both reviews and original manuscripts on mechanisms of alternative splicing, detection and analysis of isoforms, their value as diagnostic and/or prognostic factors, and splicing-related therapeutic approaches will be welcome. We hope that both basic and clinical oncologists will be interested in this exciting field of cancer research. We are looking forward to receiving your contributions.

Guest Editor

Prof. Dr. Luis Franco

1. Department of Biochemistry and Molecular Biology, Universitat de València, 46010 Valencia, Spain
2. Department of Oncology, Institute of Health Research INCLIVA, 46010 Valencia, Spain

Deadline for manuscript submissions

closed (15 May 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/119618

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)